{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:41:39Z","timestamp":1794814899878,"version":"4.9.1"},"reference-count":69,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>High tumor burden negatively affects responses to anti-CD19 chimeric antigen receptor T-cell (CART) therapy in large B-cell lymphoma (LBCL). Therefore, bridging therapy (BT) is crucial for disease control before infusion. Here, we retrospectively compared polatuzumab vedotin (PV) combined with rituximab (PV-R) \u00b1 bendamustine (PV-BR) in a cohort of 200 patients with LBCL enrolled in the prospective, multicenter, observational CART\u2013Societ\u00e0 Italiana di Ematologia (SIE) study. Commercial CARTs were infused between July 2020 and January 2025. Patients received BT with either PV-BR (n = 122) or PV-R (n = 78). At median follow-up of 11.9 months, the median progression-free survival (PFS) and overall survival (OS) in the entire cohort were 10.1 and 35.1 months after CART, respectively. When comparing PV-BR\u2013 with PV-R\u2013treated groups, patient characteristics at CART eligibility, objective response rates to BT (52.5% vs 49.4%; P = .775), median PFS (13.4 months vs 7.4 months; P = .556), and median OS (not reached vs 29.0 months; P = .954) were similar. Hematological toxicities after BT were higher with PV-BR than PV-R (36.4% vs 18.2%; P = .010; grade \u22653, 16.1% vs 6.5%; P = .048), as were rates of neurotoxicity after CART (31.1% vs 15.4%; P = .019). Rates of cytokine release syndrome and infections were comparable between the 2 groups. High tumor burden at CART infusion was independent risk factor for both PFS and OS. Our findings confirmed the role of BT and suggested that PV regimens may effectively control the disease during T-cell manufacturing. Responses and survival were similar between PV-R and PV-BR, with PV-R showing a trend toward lower toxicity, including reduced neurotoxicity, supporting its potential as a targeted, well-tolerated bridging regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018749","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:31:43Z","timestamp":1778009503000},"page":"4657-4670","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Polatuzumab vedotin\u2013containing regimens as bridge to CART: analysis from the CART-SIE study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-8712","authenticated-orcid":false,"given":"Giulia","family":"Gabrielli","sequence":"first","affiliation":[{"name":"1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[{"name":"2Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-0098","authenticated-orcid":false,"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[{"name":"3Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Tisi","sequence":"additional","affiliation":[{"name":"4Hematology Unit, San Bortolo Hospital, Azienda Unit\u00e0 Locale Socio-Sanitaria n. 8 \"Berica,\" Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Galli","sequence":"additional","affiliation":[{"name":"5Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Dipartimento di Scienze di Laboratorio ed Ematologiche, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3721-0004","authenticated-orcid":false,"given":"Ilaria","family":"Cutini","sequence":"additional","affiliation":[{"name":"6Struttura Organizzativa Dipartimentale Ematologia, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-9623","authenticated-orcid":false,"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[{"name":"7Hematology, Department of Translational and Precision Medicine, University Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-3648","authenticated-orcid":false,"given":"Livia","family":"Donzelli","sequence":"additional","affiliation":[{"name":"7Hematology, Department of Translational and Precision Medicine, University Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"8Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \"Bianchi-Melacrino-Morelli,\" Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[{"name":"8Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \"Bianchi-Melacrino-Morelli,\" Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Crescimanno","sequence":"additional","affiliation":[{"name":"9Unit\u00e0 Operativa Oncoemataologia e Programma Trapianti Cellule Staminali Ematopoietiche e Immunoterapia Cellulare Dipartimento Oncologico La Maddalena, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-7341","authenticated-orcid":false,"given":"Giuseppe","family":"Petruzzellis","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Bone Marrow Transplant, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3401-1309","authenticated-orcid":false,"given":"Federico","family":"Stella","sequence":"additional","affiliation":[{"name":"3Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"11Unit\u00e0 di Ematologia e Centro Trapianto di Midollo Osseo, Sezione di Biomedicina di Innovazione, Dipartimento di Ingegneria per la Medicina di Innovazione, Universit\u00e0 degli Studi di Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-2040","authenticated-orcid":false,"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[{"name":"11Unit\u00e0 di Ematologia e Centro Trapianto di Midollo Osseo, Sezione di Biomedicina di Innovazione, Dipartimento di Ingegneria per la Medicina di Innovazione, Universit\u00e0 degli Studi di Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-9028","authenticated-orcid":false,"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[{"name":"12Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, Azienda Socio Sanitaria Territoriale-Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Angelillo","sequence":"additional","affiliation":[{"name":"13Lymphoma Unit, University Vita-Salute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Brunello","sequence":"additional","affiliation":[{"name":"14Struttura Complessa a Direzione Universitaria Ematologia, Azienda Ospedaliero-Universitaria SS Antonio e Biagio e C. Arrigo, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-6770","authenticated-orcid":false,"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, and Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mannina","sequence":"additional","affiliation":[{"name":"16Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Humanitas, Cancer Center, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Novo","sequence":"additional","affiliation":[{"name":"17Division of Hematology, Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-9969","authenticated-orcid":false,"given":"Giovanni","family":"Grillo","sequence":"additional","affiliation":[{"name":"18Dipartimento di Ematologia e trapianto di midollo, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9911","authenticated-orcid":false,"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[{"name":"19Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"3Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"26","key":"2026071409570518800_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071409570518800_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"2026071409570518800_bib3","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026071409570518800_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"2026071409570518800_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"10254","key":"2026071409570518800_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"suppl 1","key":"2026071409570518800_bib7","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026071409570518800_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"2026071409570518800_bib9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026071409570518800_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026071409570518800_bib11","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"key":"2026071409570518800_bib12","unstructured":"US Food and Drug Administration\n          . FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma. Accessed 1 May 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-breyanzi-lisocabtagene-maraleucel-second-line-treatment-large-b."},{"key":"2026071409570518800_bib13","unstructured":"European Medicine Agency\n          . Breyanzi, Lisocabtagene Maraleucel. Accessed 1 May 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/breyanzi."},{"issue":"10","key":"2026071409570518800_bib14","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"2026071409570518800_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-T in large B-cell lymphoma - the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2026071409570518800_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"10","key":"2026071409570518800_bib17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"2026071409570518800_bib18","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2026071409570518800_bib19","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"2026071409570518800_bib20","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"27","key":"2026071409570518800_bib21","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026071409570518800_bib22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hon.2965","article-title":"Prognostic value of FDG-PET\/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma","volume":"40","author":"Bailly","year":"2022","journal-title":"Hematol Oncol"},{"issue":"7","key":"2026071409570518800_bib23","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/hem3.86","article-title":"Efficacy and safety of bendamustine-containing bridging therapy in R\/R LBCL patients receiving CD19 CAR T-cells","volume":"8","author":"Iacoboni","year":"2024","journal-title":"Hemasphere"},{"issue":"13","key":"2026071409570518800_bib24","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409570518800_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semradonc.2024.10.005","article-title":"The role of radiotherapy in lymphoma patients undergoing CAR T therapy: past, present, and future","volume":"35","author":"Wallington","year":"2025","journal-title":"Semin Radiat Oncol"},{"issue":"13","key":"2026071409570518800_bib26","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy prior to chimeric antigen receptor T-cells for B-cell lymphomas: an ILROG multicenter study","volume":"9","author":"Yegya-Raman","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026071409570518800_bib27","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"suppl 15","key":"2026071409570518800_bib28","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1200\/JCO.2021.39.15_suppl.7552","article-title":"Real-world evidence of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US)","volume":"39","author":"Jacobson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026071409570518800_bib29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","article-title":"A multicenter real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in large B-cell lymphomas","volume":"5","author":"Stella","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2026071409570518800_bib30","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"key":"2026071409570518800_bib31","unstructured":"European Medicine Agency\n          . Polivy, Polatuzumab Vedotin. Accessed 1 May 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/polivy."},{"issue":"suppl 15","key":"2026071409570518800_bib32","doi-asserted-by":"crossref","first-page":"e19070","DOI":"10.1200\/JCO.2016.34.15_suppl.e19070","article-title":"A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed\/refractory b-cell non-Hodgkin lymphoma: a comparison with non-Japanese DCS4968g study","volume":"34","author":"Hatake","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026071409570518800_bib33","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody\u2013drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026071409570518800_bib34","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026071409570518800_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2026071409570518800_bib36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2026071409570518800_bib37","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026071409570518800_bib38","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3109\/10428194.2015.1106536","article-title":"Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study","volume":"57","author":"Arcari","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2026071409570518800_bib39","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026071409570518800_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2026071409570518800_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Vacirca","year":"2014","journal-title":"Ann Hematol"},{"issue":"11","key":"2026071409570518800_bib42","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"2026071409570518800_bib43","doi-asserted-by":"crossref","first-page":"e250048","DOI":"10.6004\/jnccn.2025.0048","article-title":"NCCN Guidelines\u00ae insights: B-cell lymphomas 3.2025","volume":"23","author":"Zelenetz","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2026071409570518800_bib44","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"issue":"S2","key":"2026071409570518800_bib45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hon.3163_131","article-title":"Bendamustine lymphodepletion triggers reduced inflammatory cytokines and decreased toxicities after both 4-1bb- and Cd28-costimulated Cart19 for non-Hodgkin lymphoma","volume":"41","author":"Ghilardi","year":"2023","journal-title":"Hematological Oncol"},{"issue":"3","key":"2026071409570518800_bib46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","article-title":"Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines","volume":"8","author":"Ghilardi","year":"2024","journal-title":"Blood Adv"},{"issue":"26","key":"2026071409570518800_bib47","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071409570518800_bib48","unstructured":"Italian observational study on CAR-T therapy for lymphoma (CART-SIE). ClinicalTrials.gov identifier: NCT06339255. Updated 1 March 2024. Accessed 12 May 2026. https:\/\/clinicaltrials.gov\/study\/NCT06339255."},{"issue":"27","key":"2026071409570518800_bib49","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026071409570518800_bib50","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2026071409570518800_bib51","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2026071409570518800_bib52","doi-asserted-by":"crossref","first-page":"77.e71","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2026071409570518800_bib53","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","article-title":"Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2026071409570518800_bib54","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41375-025-02582-x","article-title":"Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy","volume":"39","author":"Iacoboni","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"2026071409570518800_bib55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"2026071409570518800_bib56","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"35","key":"2026071409570518800_bib57","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026071409570518800_bib58","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2026071409570518800_bib59","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1097\/HS9.0000000000000798","article-title":"Real-world outcomes of relapsed\/refractory diffuse large B-cell lymphoma treated with polatuzumab vedotin-based therapy","volume":"6","author":"Argnani","year":"2022","journal-title":"HemaSphere"},{"issue":"2","key":"2026071409570518800_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"key":"2026071409570518800_bib61","doi-asserted-by":"crossref","first-page":"1459067","DOI":"10.3389\/fphar.2025.1459067","article-title":"Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database","volume":"16","author":"Wu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"2026071409570518800_bib62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/10428194.2020.1824069","article-title":"Outcome of relapsed\/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience","volume":"62","author":"Segman","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2026071409570518800_bib63","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1038\/s41591-022-02069-7","article-title":"Author correction: gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"29","author":"Smith","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"2026071409570518800_bib64","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","article-title":"A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","volume":"29","author":"Stein-Thoeringer","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"2026071409570518800_bib65","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"2026071409570518800_bib66","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","article-title":"Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration","volume":"8","author":"Kostopoulos","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026071409570518800_bib67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.19453","article-title":"Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK","volume":"205","author":"Kuhnl","year":"2024","journal-title":"Br J Haematol"},{"key":"2026071409570518800_bib68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"issue":"4","key":"2026071409570518800_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4657\/2530823\/blooda_adv-2025-018749-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4657\/2530823\/blooda_adv-2025-018749-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:57:21Z","timestamp":1784037441000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4657\/568181\/Polatuzumab-vedotin-containing-regimens-as-bridge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":69,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018749","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,29]]}}}